New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
Related Experiment Videos
H E Jones1, C M Dutkowski, D Barrow
1Tenovus Cancer Research Centre, University of Wales College of Medicine, Cardiff, UK.
Abstract:
The effect of an EGF-R selective tyrosine kinase inhibitor ZM252868 was evaluated on the proliferation of PC-3 and DU-145 prostate cancer cell lines, which are purported to utilize an EGF-R-mediated autocrine pathway for regulation of cell growth. Basal growth of DU-145 cells was inhibited in a dose-dependent manner by the inhibitor, showing a 70% reduction at 1 microM, whilst the growth of PC-3 cells was not affected at this concentration. In the presence of 0.1 microM inhibitor, EGF and TGF alpha-stimulated DU-145 cell growth was decreased to below basal levels, while only TGF alpha-stimulated PC-3 cell growth was inhibited at a 1-microM concentration. Any growth responses to aFGF, bFGF, KGF, IGF1 and PDGF by DU-145 and PC-3 cells were unaffected by the inhibitor at concentrations of 1 microM or less. Additionally, the distribution of immunoreactive EGF-R varied between DU-145 and PC-3 cells, with EGF-R being predominately located on the cell membrane and in the cytoplasm, respectively.
Insights
A tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGF-R) selectively inhibited prostate cancer cell growth. DU-145 cells showed significant inhibition, while PC-3 cells demonstrated limited response to this targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Prostate cancer cell lines PC-3 and DU-145 are hypothesized to use autocrine pathways mediated by the epidermal growth factor receptor (EGF-R) for growth regulation.
- Understanding the role of EGF-R signaling is crucial for developing targeted therapies in prostate cancer.
Purpose of the Study:
- To investigate the effect of the selective EGF-R tyrosine kinase inhibitor ZM252868 on the proliferation of PC-3 and DU-145 prostate cancer cell lines.
- To determine the differential sensitivity of these cell lines to EGF-R inhibition.
Main Methods:
- Treatment of PC-3 and DU-145 cells with varying concentrations of ZM252868.
- Assessment of basal and growth factor-stimulated (EGF, TGF-alpha, aFGF, bFGF, KGF, IGF1, PDGF) cell proliferation.
- Immunohistochemical analysis of EGF-R distribution in both cell lines.
Main Results:
- ZM252868 inhibited basal growth of DU-145 cells in a dose-dependent manner (70% reduction at 1 microM), but did not affect PC-3 cell growth at this concentration.
- EGF and TGF-alpha-stimulated DU-145 cell growth was reduced below basal levels by 0.1 microM inhibitor.
- TGF-alpha-stimulated PC-3 cell growth was inhibited at 1 microM, while other growth factors showed no effect on either cell line at concentrations up to 1 microM.
- Immunoreactive EGF-R was localized to the cell membrane in DU-145 cells and the cytoplasm in PC-3 cells.
Conclusions:
- The EGF-R tyrosine kinase inhibitor ZM252868 exhibits differential effects on prostate cancer cell proliferation, with DU-145 cells being more sensitive.
- The distinct localization of EGF-R in PC-3 and DU-145 cells may contribute to their varied responses to EGF-R targeted therapy.
- These findings highlight the potential of targeting EGF-R signaling in specific prostate cancer contexts.